Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone

NCT01512108 on ClinicalTrials.gov · last registry update 2017-12-18

Finished 26 April 2013, after enrolling 363 people. Primary outcome, as filed: Incidence of Treatment Emergent Adverse Events (AEs). liraglutide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 363
Started: 2012-01-10
Primary completion: 2013-04-26 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Incidence of Treatment Emergent Adverse Events (AEs)

Conditions studied

Diabetes · Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.